6-Quinazolinesulfonamide,7-chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo- cas no:17560-51-9
Synonyms: Metenix;Diulo;6-Quinazolinesulfonamide,7-chloro-1,2,3,4-tetrahydro-2-methyl-4-oxo-3-o-tolyl- (8CI);2-Methyl-3-(o-tolyl)-6-sulfamyl-7-chloro-1,2,3,4-tetrahydro-4-quinazolinone;Metozalone;Mykrox;Normelan;Oldren;SR 720-22;Xuret;Zaroxolyn;
Name6-Quinazolinesulfonamide,7-chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo-
CAS17560-51-9
SynonymsMetenix;Diulo;6-Quinazolinesulfonamide,7-chloro-1,2,3,4-tetrahydro-2-methyl-4-oxo-3-o-tolyl- (8CI);2-Methyl-3-(o-tolyl)-6-sulfamyl-7-chloro-1,2,3,4-tetrahydro-4-quinazolinone;Metozalone;Mykrox;Normelan;Oldren;SR 720-22;Xuret;Zaroxolyn;
EINECS(EC#)241-539-3
Molecular FormulaC16H16ClN3O3S
Molecular Weight365.83
AppearanceWhite
to off-white crystalline powder
refractive index1.624
storage tempStore in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances. Store protected from light.
Hazard UN
NO.
Safety
Human systemic effects by ingestion: general anesthesia, convulsions, and muscle contractions. An experimental teratogen. Experimental reproductive effects. When heated to decomposition it emits Cl−, SOx, and NOx
RTECS of Zaroxolyn (CAS NO.17560-51-9): VA1700000
| Organism |
Test Type |
Route |
Reported Dose (Normalized Dose) |
Effect |
Source |
| man |
TDLo |
oral |
2mg/kg/2W-I (2mg/kg) |
VASCULAR: STRICTIRA; CJAMGES OM VESSE;S |
Postgraduate Medical Journal. Vol. 67, Pg. 860, 1991. |
| mouse |
LD50 |
intraperitoneal |
> 1500mg/kg (1500mg/kg) |
BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) |
United States Patent Document. Vol. #3360518, |
| mouse |
LD50 |
oral |
> 5gm/kg (5000mg/kg) |
|
United States Patent Document. Vol. #3360518, |
| mouse |
LD50 |
subcutaneous |
> 5gm/kg (5000mg/kg) |
|
Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 24, Pg. 261, 1982. |
| rat |
LD50 |
intraperitoneal |
> 5gm/kg (5000mg/kg) |
|
Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 24, Pg. 261, 1982. |
| rat |
LD50 |
oral |
> 5gm/kg (5000mg/kg) |
|
Drugs in Japan Vol. 6, Pg. APP-20, 1982. |
| rat |
LD50 |
subcutaneous |
> 5gm/kg (5000mg/kg) |
|
Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 24, Pg. 261, 1982. |
| women |
TDLo |
oral |
150ug/kg (0.15mg/kg) |
BEHAVIORAL: GENERAL ANESTHETIC
BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD
BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY) |
British Medical Journal. Vol. 1, Pg. 1381, 1976. |
